De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy.

ABSTRACT:

Background

The benefits of de-escalation of P2Y₁₂ inhibition after percutaneous coronary intervention (PCI) may differ by high bleeding risk (HBR) status.

Aims

We investigated the efficacy and safety of de-escalation from ticagrelor to clopidogrel after PCI by HBR status.

Methods

This is a non-prespecified post hoc analysis of the TicAgrelor Versus CLOpidogrel in Stabilized Patients with Acute Myocardial Infarction (TALOS-AMI) trial. Net adverse clinical events (a composite of cardiovascular death, myocardial infarction, stroke, or Bleeding Academic Research Consortium [BARC] bleeding type 2, 3, or 5) at 1 year post-PCI were compared between the de-escalation (clopidogrel plus aspirin) and the active control (ticagrelor plus aspirin) groups by HBR status, a

SUBMITTER: Kim MC 

PROVIDER: S-EPMC10687647 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature